학술논문
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Document Type
Article
Author
Fraser, G.A.M.; Chanan-Khan, A.; Demirkan, F.; Santucci Silva, R.; Grosicki, S.; Janssens, A.; Mayer, J.; Bartlett, N.L.; Dilhuydy, M.-S.; Loscertales, J.; Avigdor, A.; Rule, S.; Samoilova, O.; Pavlovsky, M.A.; Goy, A.; Mato, A.; Hallek, M.; Cramer, P.; Salman, M.; Tamegnon, M.; Sun, S.; Nottage, K.; Connor, A.; Balasubramanian, S.; Schuier, N.; Howes, A.
Source
In: Leukemia and Lymphoma . (Leukemia and Lymphoma, 2020, 61(13):3188-3197)
Subject
Language
English
ISSN
10292403
10428194
10428194